Scholars Central

Conference abstractPublished 2012

Chromium dinicocysteinate supplementation decreases vascular inflammation and Insulin resistance in type 2 diabetic patients mediated by Cysteine up regulation of Insulin signaling pathways of glucose metabolism

Authors: SK Jain, P Manna, R Hoeldtke, SN. Levine, PF Bass

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Chromium and cysteine supplementation have been shown to improve glucose metabolism in animal studies. This study examined the hypothesis that chromium dinicocysteinate (CDNC), a complex of chromium and L-cysteine, is beneficial in lowering oxidative stress, vascular inflammation and glycemia in type 2 diabetic patients (T2D). Cell culture studies using monocytes and adipocytes models were performed to delineate the molecular mechanisms by which L-cystiene supplementation supplementation increases the glucose utilization. Diabetic patients enrolled in this study were given placebo for one month for stabilization and then randomized into one of three groups: placebo (P), chromium picolinate (CP) or CDNC, after which they received daily oral supplementation for 3 months. Of the 100 patients enrolled in the study, 74 patients completed it. There were 25 patients in P group, 25 in CP and 24 in CDNC supplemented group who completed the study. Blood markers of glycemia, vascular inflammation, HOMA insulin resistance and oxidative stress were determined at randomization and after 3 months of supplementation with P, CP or CDNC. There was a significant decrease at 3 months in insulin resistance (p=0.02) and in the levels of protein oxidation (p=0.02) and TNF-α (p=0.01) in the CDNC supplemented cohort compared to baseline. However, there was no statistically significant change in these markers in the CP supplemented group compared to baseline. Insulin levels significantly decreased (p=0.01) for subjects receiving CDNC but not CP. Cell culture studies using monocytes and adipocytes models demonstrate that L-cysteine supplementation supplementation increases the glucose utilization by up-regulating the insulin stimulated (PI3K/AKT) and insulin independent (SIRT1/AMPK/PPARγ) glucose metabolism pathways essential for maintenance of glucose homeostasis. CDNC supplementation lowers insulin resistance by reducing blood levels of TNF-α, insulin, and oxidative stress in type 2 diabetic patients. Therefore, CDNC supplementation has potential as an adjunct therapy for individuals with type 2 diabetes. (Supported by NIH RO1 DK072433 and Malcolm Feist Chair in Diabetes)

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Diabetes & Metabolism
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “SK Jain”
  • BylineArticles whose byline prints “P Manna”
  • BylineArticles whose byline prints “R Hoeldtke”
  • BylineArticles whose byline prints “SN. Levine”
  • BylineArticles whose byline prints “PF Bass”